Product Information

EVB100, an electro-competent E. coli K12 strain [MC1061 araD139 delta (ara-leu)7696 delta(lac)l74 galU galK hsdR2(rK-mK+) mcrB1 rpsL(StrR)], has a birA gene stably integrated into the chromosome. Overexpression of the BirA protein is accomplished by induction with L-arabinose (0.2-0.4%). The stably integrated birA gene does not require antibiotics to be maintained. AVB100 are compatible with IPTG-inducible vectors such as Avidity"s pAC or pAN. AviTag vectors allow independent control over the expressed gene of interest and the BirA levels.

Avidity, LLC provides glycerol stocks (AVB100) or electro-competent cells (EVB100).

IMPORTANT NOTE:

Purchase of EVB100 includes a license for use only at site of purchase and may not be distributed to other sites.

License: Strain EVB100 or derivatives when purchased conveys a limited use license to the end user. This license prohibits the purchaser from selling, assigning or transferring this product to any third party without the express written consent of Avidity, L.L.C. Please review this license on the specification sheet below before purchasing this product.

提供全套的蛋白、肽生物素化的产品，其主要产品包括：生物素蛋白连接酶（BirA）；生物素化菌株；AviTag 载体；生物素化重组蛋白.

Avidity, LLC was founded in 1996 by Millard Cull, Larry Lansing, Dr. Ron Gill, and Dr. Mark Seville to develop peptide tags and molecular biology products based upon the extraordinary affinity of biotin for avidin or streptavidin. While working at Affymax as a researcher, Millard was involved in the discovery of the AviTag technology, saw its commercial potential, and obtained the exclusive rights from Affymax. He started Avidity as a reagent company that sublicenses the right to use the AviTag technology to other companies and sells products for use with the technology.